Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10886807 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL28319694 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL3984068 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL27489251 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL21811483 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL21811537 | 1.00 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL27372577 | 0.98 | NAAA (0.67) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL21811639 | 0.98 | NAAA (0.65) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL5178455 | 0.91 | — | — | |
| SCHEMBL4077569 | 0.84 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624613-A | Degradable phosphorus/silicon composite antibacterial/flame-retardant material and preparation method thereof | 浙江工业大学 | 2024-03-01 | — | — | CN | claimed |
| CN-110283320-B | Synthesis method of antibacterial hydrogel capable of being hydrolyzed under weak alkaline | 浙江工业大学 | 2021-08-24 | — | — | CN | claimed |
| CN-117624613-A | Degradable phosphorus/silicon composite antibacterial/flame-retardant material and preparation method thereof | 浙江工业大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-10 | — | — | US | disclosed |
| US-7566808-B2 | Management of ophthalmologic disorders, including macular degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| CN-101282925-A | Management of ophthalmologic disorders, including macular degeneration | HARVARD COLLEGE (US) | 2008-10-08 | — | — | CN | disclosed |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-24 | — | — | US | disclosed |
| EP-1919858-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | The President and Fellows of Harvard College (US) | 2008-05-14 | — | — | EP | disclosed |
| CN-1997359-A | Treatment of ophthalmic diseases including macular degeneration | HARVARD COLLEGE (US) | 2007-07-11 | — | — | CN | disclosed |
| WO-2007019503-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1722766-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-30 | — | — | US | disclosed |
| WO-2005079774-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-09-01 | — | — | WO | disclosed |
| US-4613614-A | Prostaglandin I2 ester and fat emulsion containing the same | THE GREEN CROSS CORPORATION (JP) | 1986-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | NAAA 4541/4885RAD52 3183/4885NPSR1 1664/4885 |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | NAAA 4647/4885RAD52 2965/4885NPSR1 1614/4885 |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | ALDH1A2, PDE6C, PDE6B | NAAA 4721/4885RAD52 3975/4885NPSR1 1666/4885 |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PDE6C, PDE6A, ALDH1A2 | NAAA 4722/4885RAD52 2929/4885NPSR1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.